Skip to main content

Table 2 Median and first and third quartile levels (pg/ml) and medianfold-increase in plasma NT-pro-BNP in patients receiving sunitinib according to clinical outcome after the first two cycles of treatment.

From: Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma

  Baseline Actual values after baseline Median fold
change to baseline
     Day15 Day30 Day45 Day75     
Clinical outcome N Median Q1-Q3 Median Q1-Q3 Median Q1-Q3 Median Q1-Q3 Median Q1-Q3 Day15 Day30 Day45 Day75
Disease progression 9 61.1 39.5-120.4 132.3 75.7-341.2 145.8 96.6-553.3 576.8 54.5-827.0 344.0 191.9-1071.0 2.8 3.9 8.9 5.4
Clinical benefit 27 149.0 97.7-535.6 179.5 80.5-337.5 215.2 87.4-380.6 241.7 111.2-555.5 260.1 120.6-637.4 1.0 1.0 0.9 0.9
p-value 0.021 0.768 0.951 0.726 0.374 0.0002 0.002 0.003 0.025
  1. Note: Q1 and Q3 are the first and third quartiles respectively
\